Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001872842 | SCV002143165 | uncertain significance | Cortical dysplasia-focal epilepsy syndrome | 2022-06-30 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs369872780, gnomAD 0.0009%). This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 880 of the CNTNAP2 protein (p.Asp880Asn). This variant has not been reported in the literature in individuals affected with CNTNAP2-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C15"). |
Prevention |
RCV003401809 | SCV004111991 | uncertain significance | CNTNAP2-related disorder | 2023-02-28 | criteria provided, single submitter | clinical testing | The CNTNAP2 c.2638G>A variant is predicted to result in the amino acid substitution p.Asp880Asn. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.00088% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/7-147844666-G-A). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |